Salix Pharmaceuticals (SLXP)
Add to Watchlists Create an AlertSalix Pharmaceuticals News
Positive Data on Roche Candidate - Analyst Blog
Zacks May 22Roche recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study
Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks May 22Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.
Data on UCB's Neupro - Analyst Blog
Zacks May 22UCB presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome.
Data on Merck KGaA's L-BLP25
May 22Data on UCB's Neupro
May 22Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Street Insider May 22Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies
Business Wire May 22Salix Pharmaceuticals, Ltd. today announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis or ulcerative proctosigmoiditis .
AbbVie Extends Galapagos Deal - Analyst Blog
Zacks May 22GLP0634 will now be developed for Crohn's disease as well.
Positive Data on Novartis' Afinitor - Analyst Blog
Zacks May 21Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3.
Positive Data on Novo Nordisk's N9-GP - Analyst Blog
Zacks May 21Novo Nordisk recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.
Actavis to Buy Warner Chilcott - Analyst Blog
Zacks May 21The acquisition is expected to be accretive to Actavis' 2014 earnings per share by more than 30%.
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SLXP | 59.47 | +0.14 | +0.24% | 3.634B |
